key: cord-0706696-j6w1mt21
authors: Staszewski, Cara; Rochelson, Burton; Krantz, David A.; Gerber, Rachel; Juhel, Hannah; Reddy, Shreya; Blitz, Matthew J.
title: Persistence of infection-induced SARS-CoV-2 seropositivity throughout gestation
date: 2021-10-02
journal: Am J Obstet Gynecol
DOI: 10.1016/j.ajog.2021.09.037
sha: cec51b6806a4ef66f00d3517f00e93aee5b23113
doc_id: 706696
cord_uid: j6w1mt21

nan

(IgG) antibodies increase approximately 2 to 3 weeks after viral infection. How long these 23 antibodies persist and how rapidly they decay has been the subject of several studies in non-24 pregnant patients, sometimes with differing results. [1] [2] [3] [4] One study in pregnant women observed 25 that neutralizing antibody titers remained stable throughout gestation. 5 Our study evaluated 26 qualitative IgG antibody responses to SARS-CoV-2 infection longitudinally throughout 27 pregnancy in an unselected cohort, shortly after the peak of the outbreak in New York, to 28 determine the frequency of waning seropositivity. 29 30 Study Design: This retrospective cohort study evaluated all patients who had first and second 31 trimester biochemical screening to detect fetal aneuploidy between May 2020 and June 2020 at 32 three hospitals within a large integrated health system in New York, and subsequently had 33 SARS-CoV-2 antibody testing during hospitalization for delivery. During the study period, 34 health system policy was to perform SARS-COV-2 polymerase chain reaction (PCR) testing on 35 all hospitalized obstetrical patients and to offer, but not require, SARS-CoV-2 antibody testing. 36

All patients were pregnant at the start of the coronavirus disease 2019 (COVID-19) pandemic 37 and delivered prior to availability of SARS-CoV-2 vaccination. For each included patient, dried 38 blood specimens collected in the first trimester and serum blood specimens collected in the 39 second trimester were retrieved from storage at -20 degree C and tested for SARS-CoV-2 IgG 40 antibodies to the nucleocapsid protein using an ELISA assay (Gold Standard Diagnostics Inc, testing at delivery. Medical records were reviewed to obtain clinical characteristics. Descriptive 46 statistics were used to evaluate the data. The Institutional Review Board approved the study protocol. Table 1 . 61 receptor binding domain of the spike protein of SARS-CoV-2 are associated with neutralization, 69 reducing the risk of reinfection. Asymptomatic or mild SARS-CoV-2 infection is associated with 70 lower peak antibody titers. 6 Waning antibody levels during pregnancy may render patients 71 susceptible to reinfection. For patients who cite past infection as justification to defer 72 vaccination, this may be an important talking point as higher antibody titers are generated after 73 vaccination than after natural infection. 7 However, it must be acknowledged that antibody 74 response alone may not be the best measure of immunity; memory B cells and T cells may 75 persist and offer some protection against reinfection even if serum antibody levels are 76 undetectable. 8 Our study is limited by use of multiple laboratory testing methods, lack of 77 quantitative antibody titers, use of stored specimens, a small sample size, potential for selection 78 and recall bias, and uncertain severity of disease among those with positive antibody testing. 79

Furthermore, the lower level of detection for these qualitative antibody assays is unknown; they 80

are not calibrated to a particular titer cut-off and manufacturer reported sensitivities are based on 81 precise timing after symptom onset or PCR-confirmed infection which are not known in this 82 study. Thus, definitive conclusions about the presence or persistence of immunity cannot be 83 made. 84 

Persistence and decay of human antibody 89 responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 90 patients

Longitudinal observation and decline of 92 neutralizing antibody responses in the three months following SARS-CoV-2 infection in 93 humans

Robust neutralizing antibodies to SARS-CoV-2 95 infection persist for months

Longitudinal analysis of antibody response 97 following SARS-CoV-2 infection in pregnancy: From the first trimester to delivery

SARS-CoV-2 in relation to symptoms in a nationwide prospective study

Coronavirus disease 2019 vaccine response in 103 pregnant and lactating women: a cohort study

Not just antibodies: B cells and T cells mediate immunity to 105 COVID-19